Close mobile menu×

Karen S. Marder, MD, MPH

Board Certifications: 
Neurology
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-6939

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Neurology

Clinical Expertise

  • Dementia
  • Huntington Disease
  • Alzheimer's Disease
  • Behavioral Disorder
  • Memory Loss

Specialties

Education & Training

  • Cornell University Medical College, NY
  • Internship: St. Luke's-Roosevelt Hospital Center
  • Residency: Columbia University Medical Center
  • Fellowship: Columbia University Medical Center

About Karen Marder

Karen Marder, MD, MPH is the Sally Kerlin Professor of Neurology at Columbia University Medical Center. She has served as the Chief of the Division of Aging and Dementia since 2001 and has directed the United Council for Neurologic Subspecialties (UCNS) fellowship in Behavioral Neurology and Neuropsychiatry since its inception.

In both research and patient care, Dr. Marder is focused on the epidemiology and treatment of cognitive, behavioral, and motor impairments in a range of neurodegenerative diseases, including Parkinson’s disease (PD), Huntington’s Disease (HD), HIV dementia, Alzheimer’s disease (AD) and related disorders.

Since 1998, Dr. Marder has been characterizing the earliest motor and non-motor signs associated with genetic forms of PD. She served as co-chair and chair of the Executive Committee of the Parkinson Study Group (2006-2012), a consortium of North American investigators participating in collaborative PD research at 120 sites. She is the founding (1991) and current director of the multidisciplinary Huntington's Disease Society of America Center of Excellence at Columbia, and also serves as associate director of the Irving Institute for Clinical and Translational Research (CTSA). In addition, Dr. Marder is co-prinicipal investigator of the Columbia University–Weill Cornell NIH-funded NeuroNEXT site, a clinical trial network whose goal is to conduct Phase II biomarker informed neurological clinical trials over a 7-year period.

Academic Titles

  • Sally Kerlin Professor of Neurology (in the Gertrude H. Sergievsky Center, in the Taub Institute on Alzheimer's Disease and the Aging Brain, and in Psychiatry) at CUMC

Administrative Positions

  • Chief, Division of Aging and Dementia
  • Associate Director, Irving Institute for Clinical and Translational Research
  • Director, Clinical Research Resource, Irving Institute
  • Director, Huntington's Disease Center

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Access (Exchange)
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Amida Care

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

MagnaCare

Medicare

  • Medicare

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • EPO
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • SelectHealth

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
Neurological Institute of New York
710 West 168th Street
New York, NY 10032
Primary

Research

Dr. Marder's research has focused on the epidemiology and treatment of cognitive, behavioral, and motor impairments in a range of neurodegenerative diseases, including Parkinson’s disease (PD), Huntington’s Disease (HD), HIV dementia, and Alzheimer’s disease (AD) and related disorders. Most recently, my focus has been on characterizing the earliest signs associated with genetic forms of PD including Parkin, LRRK2, and GBA mutations, especially in individuals with early-onset PD.

In May 2006, I was elected to a 6-year term as co-chair of the Executive Committee of the Parkinson Study Group, a consortium of North American investigators participating in collaborative PD research at 120 sites.

I established the Huntington's Disease Society of America Center of Excellence at Columbia University in 1991, which I continue to lead today. We conduct a wide range of observational research and clinical trials for people with HD and those at risk.

I am particularly interested in the knowledge and attitudes of people at risk for genetic disorders. At Columbia, I also serve as associate director of the Irving Institute for Clinical and Translational Research (CTSA) where I direct the Clinical Research Resource for adult and pediatric inpatient and outpatient research. I am also the co-Principal Investigator for the Columbia/Weill-Cornell site of the NINDS-funded NeuroNEXT clinical trial network, whose mission is to conduct Phase 2 biomarker informed studies of neurological diseases.

Research Interests

  • Neuropsychiatry/cognitive disorders

Grants

PARKINSON S PROGRESSION MARKERS INITIATIVE (PPMI) (Private)

Oct 25 2013 - Feb 17 2019

COLUMBIA UNIVERSITY MEDICAL CENTER-WEILL CORNELL MEDICAL CENTER NEXT SITE (Federal Gov)

Sep 30 2011 - Jun 30 2018

CENTER FOR RESEARCH ON ETHICAL, LEGAL AND SOCIAL IMPLICATIONS OF PSYCHIATRIC, NEUROLOGIC AND BEHAVIORAL GENETICS (Federal Gov)

May 3 2013 - May 31 2018

PBMC AND URINE EXOSOSMES IN LRRK2 AND IDIOPATHIC PD (Private)

Jan 1 2016 - Dec 31 2017

IDENTIFYING HUNTINGTONS DISEASE MARKERS BY MODERN STATISTICAL LEARNING METHODS (Federal Gov)

Aug 1 2014 - Jul 31 2017

ANALYSIS AND REPLICATION OF A GENETIC INTERACTION BETWEEN LRRK2 AND PARK16 (Private)

Oct 2 2013 - Jul 31 2016

FDG PET STUDY START-UP (Private)

Jul 1 2015 - Jun 30 2016

EFFICIENT METHODS FOR GENOTYPE-SPECIFIC DISTRIBUTIONS WITH UNOBSERVED GENOTYPES (Federal Gov)

Jul 15 2011 - Jun 30 2016

CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

Sep 30 2006 - Jun 30 2016

HDSA CENTER OF EXCELLENCE (Private)

Jan 1 2015 - Dec 31 2015

PENETRANCE OF LRRD2 IN THE MJ FOX LRRK2 COHORT CONSORTIUM (Private)

Sep 18 2013 - Sep 17 2015

CREATINE SAFETY, TOLERABILITY & EFFICACY IN HUNTINGTON S DISEASE: CREST-E (Federal Gov)

Jul 1 2014 - Jun 30 2015

PARKINSON S DISEASE, ASHKENAZI JEWS AND LRRK2: A CONSORTIUM PROPOSAL (Private)

Jul 1 2011 - Jun 30 2015

ALZHEIMER S DISEASE RESEARCH CENTER AT COLUMBIA UNIVERSITY (Federal Gov)

Jun 1 2010 - May 31 2015

HORIZON-PLUS: AN OPEN LABEL EXTENSION OF THE HORIZON PROTOCOL(DIM20) EVALUATING THE SAFETY OF DIMEBON(LATREPIRDINE) IN S (P&S Industry Clinical Trial)

May 27 2010 - May 27 2015

DAT IMAGING IN AJ LRRK2 GENE CARRIERS (LRKK2) (Private)

Dec 13 2010 - Apr 18 2015

ANALYTIC MODELS AND BIOMARKER DEVELOPMENT (Private)

Jan 1 2012 - Dec 31 2014

NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON S DISEASE (Private)

Sep 1 2012 - Aug 31 2014

A PROSPECTIVE REGISTRY STUDY IN A GLOBAL HUNTINGTON S DISEASE COHORT (ENROLL-HD) (Private)

Aug 21 2012 - Aug 20 2014

COENZYME Q10 IN HUNTINGTON S DISEASE (Federal Gov)

Sep 30 2012 - Jul 31 2014

LRRK2 MUTATIONS AND CANCER RISK (Private)

May 1 2012 - Apr 30 2014

CENTER FOR ELSI RESEARCH ON PSYCHIATRIC, NEUROLOGIC, AND BEHAVIORAL GENETICS (Federal Gov)

Jun 1 2010 - Apr 30 2014

NEUROPATHOLOGICAL TISSUE COLLECTION IN LRRK2 MUTATION CARRIERS WITH AND WITHOUT PARKINSON S DISEASE (Private)

Feb 16 2012 - Feb 15 2014

HUNTINGTON S DISEASE SOCIETY OF AMERICA CENTER OF EXCELLENCE (Private)

Oct 1 2004 - Dec 31 2013

GAIT AND MOTOR SYMPTOMS IN HEALTHY ASYMPTOMATIC RELATIVES OF PATIENTS WITH PD CARRIERS OF MUTATIONS IN THE LRRK2 GEN (Private)

Dec 1 2011 - Nov 30 2013

GENETIC EPIDEMIOLOGY OF PARKINSON S DISEASE (Federal Gov)

Jul 1 1998 - Nov 30 2013

NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON S DISEASE (Federal Gov)

Sep 1 2004 - Aug 31 2013

NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON''S DISEASE (Federal Gov)

Sep 1 2004 - Aug 31 2013

CREATINE SAFETY, TOLERABILITY & EFFICACY IN HUNTINGTON S DISEASE (CREST-E) (Federal Gov)

Jul 1 2008 - Jun 30 2013

PARKINSON S DISEASE GENETICS INITIATIVE (Private)

Jul 1 2005 - Jun 30 2013

AUTONOMIC DYSFUNCTION IN LRRK2 MUTATION CARRIERS: CHARACTERIZATION OF AUTONOMIC PROFILES OF PATIENTS WITH PD, CARRIERS OF MUTATIONS IN THE LRRK2 GENE AND NON-MANIFESTING FIRST DEGREE RELATIVES (Private)

Dec 1 2011 - Nov 30 2012

COGNITIVE ASSESSMENT BATTERY (CAB) BETA STUDY (Private)

Feb 18 2011 - Nov 30 2012

COENZYME Q10 IN HUNTINGTON S DISEASE (Federal Gov)

Dec 1 2007 - Nov 30 2012

THE ROLE OF GLUCOCEREBROSIDASE IN PARKINSON DISEASE AND COGN ITIVE IMPAIRMENT (Private)

Jul 1 2010 - Aug 31 2012

PARKINSON''S DISEASE IPS CELL LINE RESEARCH (Federal Gov)

Sep 30 2009 - Aug 31 2012

PARKINSON S DISEASE, ASHKENAZI JEWS AND LRRK2-A CONSORTIUM PROPOSAL (Private)

Jun 30 2009 - Jun 29 2012

COOPERATIVE HUNTINGTON"S OBSERVATIONAL RESEARCH TRIAL (COHOT) (Private)

Jul 1 2005 - Jun 30 2011

PROSPECTIVE HUNTINGTON AT RISK OBSERVATION (Federal Gov)

Aug 17 2004 - Jun 30 2011

PROSPECTIVE HUNTINGTON AT RISK OBSERVATION STUDY (Federal Gov)

Aug 17 2004 - Jun 30 2011

COOPERATIVE HUNTINGTON''S OBSERVATIONAL RESEARCH TRIAL (COHOR T) (SUBSTUDY) (Private)

Jul 1 2009 - Jun 30 2010

PROSPECTIVE HUNTIGTON AT RISK OBSERVATION STUDY__PHAROS (Private)

Jul 1 2006 - Jun 30 2010

PROSPECTIVE HUNTINGTON AT RISK OBSERVATION STUDY--PHAROS (Federal Gov)

Jul 1 2006 - Jun 30 2010

PARKINSONS DISEASE COLLABORATIVE STUDY OF GENETIC LINKAGE, P ROGENI (Federal Gov)

Sep 1 2000 - Jan 31 2010

NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON''S DISEASE (Private)

Aug 1 2003 - Aug 31 2009

RESPONCE OF A SAMPLE POPULATION WITH THE DELETERIOUS HD ALLELE, RESPOND-HD (Federal Gov)

Sep 26 2005 - Jul 31 2009

GENETIC EPIDEMIOLOGY OF PARKINSON"S DISEASE (Federal Gov)

Jul 1 1998 - Apr 30 2009

COENZYME Q10 IN HUNTINGTON''S DISEASE (Federal Gov)

Dec 1 2007 - Dec 10 2008

NEUROLOGICAL AIDS RESEARCH CONSORTIUM (Federal Gov)

Dec 1 1993 - Jul 31 2007

NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON''S DISEASE (Federal Gov)

Mar 1 2002 - Aug 31 2004